Trending...
- California: Governor Newsom announces judicial appointments 12.22.2025
- PODS Local Helps Residents Meet Their 2026 New Year's Resolution
- Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
- Jefferies Virtual Healthcare Conference on Thursday, June 3 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time)
- Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
- Long Beach Health Department Announces Conclusion of Healthy Active Long Beach Program Following Loss of Federal Funding
- Eric Galuppo Highlights Structural Growth Risk Facing Service Companies
- City of Long Beach Invites Public to Share Their Priorities for the 2027 City Budget at Upcoming Community Meetings
- Eric Bellinger Hosts Second Annual Christmas Hoopathon Benefiting Underserved Youth
- ECMG Releases Doom to the World: A Cthulhu Holiday Album (Volume 1)
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
Filed Under: Business
0 Comments
Latest on The Californer
- Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
- Nexar Bit Exchange Enhances Platform Infrastructure
- Jon Robert Quinn Builds Awepra, AwepraAI, and AwepraQ to Redefine the Future Beyond Social Media
- A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
- 4-Hour Work Day: Jon Robert Quinn Challenges Hustle Culture and Redefines Entrepreneurial Success
- Long Beach: City Announces Conclusion of SEED Program Following Loss of Federal Funding, Launches LBPL Creativity Lab
- Long Beach Health Department Launches Expanded Fund Initiatives to Support Community Health and Local Nonprofits
- California turns winter season rain into future water supply
- City of Long Beach Extends Inclement Weather Action Plans
- Louisa Gillis at North Coast Repertory Theatre
- California: Governor Newsom declares states of emergency related to multiple severe weather events in 2025
- California: Governor Newsom deploys dedicated teams to fight crime in Stockton, building on existing successful partnerships
- BanksyLee.com Is Redefining Daily Financial Insight for the Modern Investor
- California: Governor and LA Rises announce new online resource to further help LA fire survivors navigate rebuilding
- California: Governor Newsom's SAFE Task Force partners with Sacramento to clear encampment
- Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
- Prop 1 brings new projects creating hundreds of housing units for Californians, including veterans
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence